Updates in the Treatment of Advanced/Recurrent Endometrial Cancer: Data from the NRG-GY018 StudyMay 18th 2023
Ramez Eskander, MD, presents data from the GY018 study investigating pembrolizumab versus placebo in addition to carboplatin/paclitaxel in patients with advanced/recurrent endometrial cancer.
Updates in the Treatment of Advanced/Recurrent Endometrial Cancer: Data from the RUBY TrialMay 18th 2023
Dr Robert Coleman details data from the RUBY trial investing the role of checkpoint inhibitor dostarlimab in combination with chemotherapy for the treatment of advanced/recurrent endometrial cancer.
2 Clarke Drive
Cranbury, NJ 08512